Concepedia

Marianne T. Sweetser

MT

46

Publications

11.6K

Citations

35

H-Index

1988

Active since

Affiliations

Alnylam Pharmaceuticals (United States)(Current)

Biogen (United States)

University College London

Inserm

Heidelberg University

Marianne T. Sweetser is an author at Alnylam Pharmaceuticals (United States) specializing in medicine, immunology, and immunotherapy.

Top concepts

Publications per year

1988–2023

46

Publications

46

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

David Adams, Alejandra González‐Duarte, William O’Riordan et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

Ralf Gold, Ludwig Kappos, Douglas L. Arnold et al. · New England Journal of Medicine · 2012 · 1.7K citations · Full text

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

Robert J. Fox, David H. Miller, J. Theodore Phillips et al. · New England Journal of Medicine · 2012 · 1.3K citations · Full text

A Critical Role for Dnmt1 and DNA Methylation in T Cell Development, Function, and Survival

Peggy P. Lee, David Fitzpatrick, Caroline Beard et al. · Immunity · 2001 · 1.3K citations · Full text

, , +14

Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria

Manisha Balwani, Eliane Sardh, Paolo Ventura et al. · New England Journal of Medicine · 2020 · 562 citations · Full text

Rows per page

1–5 of 46